Osimertinib (Tagrosso) dose for brain mets – pro
Lierature lists doses of 80 mg adn 160 mg per day in different studies for treatment of metastatic brain disease Goldstein in 202o found that simertinib 160 mg is feasible and may offer a therapeutic alternative for patients with isolated intracranial progression on osimertinib standard (80 mg) dose. Further studies on CNS osimertinib pharmacokinetics are needed to test this hypothesis. However, most studies used 80 mg and found affeciveness, so I disagree that 160mg is the standard dose.
Sun Y, Ai X, Lu S. Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report. Transl Lung Cancer Res. 2022 Feb;11(2):323-330
Peled N, Kian W, Inbar E, Goldstein IM, Zemel M, Rotem O, Rozenblum AB, Nechushtan H, Dudnik E, Levin D, Zer A, Keren-Rosenberg S, Yust-Katz S, Fuchs V, Remilah AA, Shelef I, Roisman LC. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neurooncol Adv. 2021 Dec 27;4(1):vdab188..